Sugi Predict

Sugi Predict / Compounds / SCHEMBL9230833

SCHEMBL9230833

SCHEMBL9230833

CNc1ccccc1OC(F)F

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.51
▸ LRRK2 Q5S007 1/20 0.51
▸ HTT P42858 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ ALOX12 P18054 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ SLC22A12 Q96S37 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ ULK1 O75385 1/20 0.42
▸ APP P05067 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2095787 0.81 ALDH1A1 (0.50) KMT2ALRRK2SMN1; SMN2ALDH1A1MEN1
SCHEMBL2044836 0.79 KMT2A (0.56) KMT2AHTTSMN1; SMN2ALOX12ALDH1A1
SCHEMBL17839656 0.79 KMT2A (0.51) KMT2ALRRK2HTTSMN1; SMN2ALOX12
SCHEMBL29666377 0.79 KMT2A (0.51) KMT2ALRRK2HTTSMN1; SMN2ALOX12
SCHEMBL21966132 0.79 ALOX12 (0.52) KMT2ALRRK2HTTSMN1; SMN2ALOX12
SCHEMBL18878172 0.79 MAPT (0.44) KMT2ALRRK2HTTSMN1; SMN2ALOX12
SCHEMBL28007720 0.79 ALDH1A1 (0.45) KMT2ALRRK2HTTSMN1; SMN2ALOX12
SCHEMBL19381227 0.78 APP (0.41) KMT2ALRRK2HTTSMN1; SMN2ALOX12
SCHEMBL6130398 0.78 APP (0.41) KMT2ALRRK2HTTSMN1; SMN2ALOX12
Hydrochloric Acid SCHEMBL4555835 0.77 KMT2A (0.48) KMT2ALRRK2HTTSMN1; SMN2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115181092-B Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2024-05-03 — — CN disclosed
CN-114315796-B Compounds used as HPK1 kinase inhibitor, preparation method and application thereof 中国药科大学 2024-03-26 — — CN disclosed
CN-115181092-A Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2022-10-14 — — CN disclosed
CN-112279837-B Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2022-08-09 — — CN disclosed
CN-114315796-A Compound used as HPK1 kinase inhibitor and preparation method and application thereof 中国药科大学 2022-04-12 — — CN disclosed
CN-111747954-B Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2021-08-24 — — CN disclosed
CN-112279837-A Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2021-01-29 — — CN disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 — — EP disclosed
CN-112055709-A Pyrazine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2020-12-08 — — CN disclosed
EP-3151669-B1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-10-28 — — EP disclosed
US-20160008362-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-01-14 — — US disclosed
CN-104619709-A Imidazopyridine derivatives as modulators of TNF activity UCB PHARMA SA 2015-05-13 — — CN disclosed
CN-104428293-A TNF -alpha modulating benzimidazoles UCB PHARMA SA 2015-03-18 — — CN disclosed
US-8946266-B2 Substituted triazole and imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-02-03 — — US disclosed
US-8946266-B2 Substituted triazole and imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-02-03 — — US disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 — — US disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 — — US disclosed
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-05-31 — — US disclosed
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-05-31 — — US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160008362-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE NR0B1, NR2E3, NR0B2 KMT2A 1042/4885LRRK2 875/4885HTT 3922/4885
US-20120135981-A1 NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A KMT2A 2877/4885LRRK2 1530/4885HTT 1131/4885
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 KMT2A 2175/4885LRRK2 4263/4885HTT 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.